Chief of Valeant mini-me Concordia sues short seller for libel


Concordia can add trouble with a short seller to the list of things it wishes it didn’t share in common with Valeant Pharmaceuticals.

The drugmaker’s CEO, Mark Thompson, is suing Marc Cohodes--a former employee of short-selling hedge fund Rocker Partners--for libel, The Wall Street Journal reports.

Thompson is seeking $4 million Canadian dollars, alleging in documents reviewed by the WSJ that he has “suffered damage to his reputation and feelings” thanks to “false and defamatory statements” by Cohodes.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

It all started with an April TV appearance by Cohodes on a Canadian financial news channel. He brought up Thompson’s employment history at Biovail--now part of Valeant--which in 2008 paid $10 million to U.S. securities regulators to settle accounting fraud charges.

“The management of Concordia, their past gig was at something called Biovail, which I was short a long time ago [and] was a complete and utter fraud. So [Mr.] Thompson has a history of nonsense when he was at Biovail,” Cohodes said.

The way Thompson sees it, those statements were understood to mean that he himself had committed fraud while at Biovail. And as he argues in the lawsuit, Cohodes “has launched a campaign to manipulate downward the price of Concordia shares by, among other things, criticizing Mr. Thompson.”

Meanwhile, shares of Concordia--which has been tagged as a mini-Valeant thanks to its similar strategy, which includes price hikes, rampant M&A and a large debt load--have taken a beating over the past 12 months, sinking by nearly 80%, the WSJ notes.

And Concordia isn’t alone. Specialty peers Mallinckrodt, Endo, Horizon and others have all suffered on the stock market since Valeant’s own decline began last year. That downfall, set in motion by governmental drug-pricing pushback, was propelled by short-seller Andrew Left of Citron Research, who in October claimed Valeant had used its specialty pharmacy network to inflate its top line.

- read the WSJ story (sub. req.)
- see Cohodes' response 

Special Report: The most influential people in biopharma today - 2016 - J. Michael Pearson - Valeant

Related Articles:
Compatriot drugmaker shares Valeant's appetite for price hikes
Deal stalker Concordia snaps up Amdipharm in 'pivotal turning point' for M&A strategy
Valeant's shares nosedive on short seller's 'phantom sales' allegations
Watch out, Valeant. Concordia's joining the buy-to-grow pharma business
Concordia scores ex-Big Pharma drugs in $1.2B Covis buyout


Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.